Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/IIa NN2802 in healthy volunteers and antihistamine-refractory chronic spontaneous urticaria
ChiCTR2600134508Phase 2Not yet recruiting
- Sponsor
- Hangzhou First People's Hospital
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of SLRN-517 in chronic idiopathic urticaria (CIU) (6 arms), sponsored by Hangzhou First People's Hospital. Primary endpoint: Safety parameters. Planned start May 2026; status: not yet recruiting.
02
Drugs
SLRN-517
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on ChiCTR2600134508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134508.